Innate Therapeutics initiates MIS416 Phase 2a clinical study in patients with progressive multiple sclerosis

August 31, 2017

The study, to be conducted at the Primorus clinical trial unit in Christchurch, New Zealand, will enroll a total of 24-30 patients. The initial stage of the trial, involving the first 12-18 patients, will examine the safety, tolerability and pharmacokinetics of intravenously administered MIS416 to determine a recommended therapeutic dose and dosing interval for the confirmatory portion of the trial. The dose confirmation portion of the study will treat patients weekly at the recommended dose level for a period of six months. Besides safety and tolerability, the end point for this confirmatory portion of the study will be to document any changes in MS clinical status, as determined by several standard MS scales for clinical evaluation, as well as frequency of relapses and signs of clinical activity on serial brain MRI scans. Innate Therapeutics expects to complete the study around the end of 2011.

Innate Therapeutics is additionally conducting preclinical studies with MIS416 in other applications, including as a potential co-therapy with other treatments for cancer, and in the treatment of infectious diseases.

Source: Innate Therapeutics